NAGE logo

Niagen Bioscience Inc. (NAGE)

$2.04

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NAGE

Market cap

$161561682

EPS

0.12

P/E ratio

14.9

Price to sales

1.65

Dividend yield

--

Beta

2.117588

Price on NAGE

Previous close

$2.01

Today's open

$2

Day's range

$1.95 - $2.05

52 week range

$1.95 - $7.12

Profile about NAGE

CEO

Rob Fried

Employees

117

Headquarters

Los Angeles, CA

Exchange

NASDAQ Capital Market

Shares outstanding

79196903

Issue type

Common Stock

NAGE industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NAGE

Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Aging--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it will support the Sixth Annual Longevity Summit taking place from December 9 to 10, 2026, at the Buck Institute for Research on Aging in Novato, California. The Summit, themed “The Future of Medicine: Eliminating Diseases of Aging,” convenes researchers, investors and government organizations to dis.

news source

Business Wire • Nov 16, 2026

news preview

Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has partnered with Truemed to provide qualified customers the option to purchase the Niagen™ At-Home Injection Kit using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, now available through its Niagen™ Plus telehealth platform. Qualified customers may use HSA/FSA funds.

news source

Business Wire • Nov 12, 2026

news preview

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: A.G.P. Virtual Consumer Showcase Virtual showcase offering consumer company management teams a platform to share their story with the investment community Location: Virtual Date: November 11 - 12, 2026 Format: Fireside chat.

news source

Business Wire • Nov 9, 2026

news preview

Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript

Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026. Third Quarter 2026 Financial and Business Highlights Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company's website grew by 13% year-over-year. Gross margin of 62.

news source

Business Wire • Nov 4, 2026

news preview

Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates

Niagen Bioscience (NAGE) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen™ At-Home Injection Kit, featuring the Company's first ready-to-inject liquid formulation with Niagen™ (patented nicotinamide riboside, or NR), the most studied, high-quality NAD+ precursor brand available, now availabl.

news source

Business Wire • Oct 22, 2026

news preview

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Beauty--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen® (patented nicotinamide riboside, or NR.

news source

Business Wire • Oct 20, 2026

news preview

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesda.

news source

Business Wire • Oct 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Niagen Bioscience Inc.

Open an M1 investment account to buy and sell Niagen Bioscience Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NAGE on M1